Nurix Therapeutics, Inc.
As of Oct 22, 2026, Nurix Therapeutics is in Stage 3, the topping phase, now in its first week (since Oct 20, 2026). It closed at $25.51, 8.2% below its 52-week high and above its 200-day average, which is rising.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer,… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is NRIX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
NRIX among Biotechnology28th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …28 | NRIX | Stage 3 · wk 1 | 97 | +6.8% |
Nurix Therapeutics: quick answers
What stage is Nurix Therapeutics in?
As of Oct 22, 2026, Nurix Therapeutics (NRIX) is in Stage 3, the topping phase. It entered Stage 3 on Oct 20, 2026 and is in its first week there. What the four stages mean
Is Nurix Therapeutics in an uptrend?
Its uptrend has stalled. Nurix Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 27.9% above its 200-day average, which is rising.
How far is Nurix Therapeutics from its 52-week high?
Nurix Therapeutics closed at $25.51 on Oct 22, 2026, 8.2% below its 52-week high of $27.79. Its 52-week low is $10.40.
How has Nurix Therapeutics performed over the past year?
As of Oct 22, 2026, Nurix Therapeutics is up 144.8% over the past year and up 41.3% so far in 2026.
Which sector and industry is Nurix Therapeutics in?
Nurix Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc. for co-development and co-commercialization of multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.